drugset
drugset / Trial / NCT02561156

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

NCT02561156 ↗

Phase 1 Completed 88 enrolled Neurocrine Biosciences Takeda · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of TAK-653 when administered as single and multiple oral doses at escalating dose levels in healthy participants.

Timeline

Start
2015-08-26
Primary completion
2017-09-11
Completion
2017-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject OSAVAMPATOR Small molecule 0.3 mg Oral
Subject OSAVAMPATOR Small molecule 1 mg Oral
Subject OSAVAMPATOR Small molecule 3 mg Oral
Subject OSAVAMPATOR Small molecule 5 mg Oral
Subject OSAVAMPATOR Small molecule 6 mg Oral
Subject OSAVAMPATOR Small molecule 9 mg Oral
Subject OSAVAMPATOR Small molecule 18 mg Oral

Indications

depressive disorder